Donald Brown, Chief Executive Officer
Mr. Brown has been Chief Executive Officer of Arteriocyte, since becoming its first employee in 2004. To date, he has raised $60 Million in capital for the company, and has built a team of 76 employees worldwide that hold true to the company’s vision of “helping patients heal faster”.
Arteriocyte’s early cell therapy development targeted concentrating and delivering marrow-derived stem cells to myocardial tissues in patients with chronic ischemia. In October of 2007, the six employees of Arteriocyte partnered with DW Healthcare Partners to create Arteriocyte Medical Systems Inc., to acquire the Magellan rapid bedside fractionation device brand from Medtronic. The Magellan acquisition . . .
Meghan Samberg, PhD, Vice President and General Manager
As Compass Biomedical’s Vice President and General Manager, Meghan is responsible for leading laboratory and preclinical evaluations for early stage product development. She works closely with both academic and industry partners to direct the research and development efforts necessary to support regulatory submissions and clinical development of new products. As a broadly trained biomedical engineer, her specialties are in skin wound healing, animal model development, nanoparticle toxicology, tissue engineering, biomaterial fabrication, and lyophilization.
Meghan holds a Bachelor of Science in Biological Engineering from the University of Georgia, a Masters of Science in Biomedical Engineering from Yale University, and a Doctorate of Philosophy from The University of North Carolina at Chapel Hill and North Carolina State University. She conducted post-doctoral research at North Carolina State University and at the United States Army Institute for Surgical Research at Fort Sam Houston, and previously led preclinical pharmacology efforts at a small drug development company specializing in nitric-oxide releasing therapies.